Davendra Sohal

10.6k total citations · 2 hit papers
167 papers, 3.5k citations indexed

About

Davendra Sohal is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Davendra Sohal has authored 167 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 109 papers in Oncology, 62 papers in Pulmonary and Respiratory Medicine and 58 papers in Cancer Research. Recurrent topics in Davendra Sohal's work include Pancreatic and Hepatic Oncology Research (70 papers), Cancer Genomics and Diagnostics (52 papers) and Renal cell carcinoma treatment (22 papers). Davendra Sohal is often cited by papers focused on Pancreatic and Hepatic Oncology Research (70 papers), Cancer Genomics and Diagnostics (52 papers) and Renal cell carcinoma treatment (22 papers). Davendra Sohal collaborates with scholars based in United States, United Kingdom and France. Davendra Sohal's co-authors include Alok A. Khorana, Philip A. Philip, Ramesh K. Ramanathan, Eileen M. O’Reilly, Daniel A. Laheru, Andrea Wang‐Gillam, Katherine A. Guthrie, Andrew M. Lowy, Andrew Hendifar and Muhammad Shaalan Beg and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Davendra Sohal

157 papers receiving 3.4k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial

2020 327 citations Michael J. Pishvaian, Edik M. Blais et al. profile →
Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma

2021 175 citations Davendra Sohal, Syed A. Ahmad et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Davendra Sohal	2.4k	1.3k	1.1k	715	711	167	3.5k
P. Murawa	3.0k 1.2×	1.1k 0.9×	1.2k 1.1×	770 1.1×	890 1.3×	47	4.1k
Robert Lim	3.1k 1.3×	1.1k 0.8×	1.4k 1.3×	534 0.7×	1.3k 1.9×	56	4.5k
Jorge Barriuso	2.4k 1.0×	815 0.6×	908 0.9×	1.1k 1.5×	979 1.4×	137	4.0k
Stefan Boeck	3.4k 1.4×	1.2k 0.9×	1.2k 1.1×	890 1.2×	805 1.1×	145	4.3k
John C. Mansour	2.1k 0.9×	847 0.7×	1.1k 1.1×	1.2k 1.7×	650 0.9×	105	3.4k
Hagen F. Kennecke	3.6k 1.5×	1.9k 1.5×	1.4k 1.4×	686 1.0×	1.4k 1.9×	156	5.5k
Miao‐Zhen Qiu	2.5k 1.1×	1.3k 1.0×	1.6k 1.5×	1.1k 1.5×	1.6k 2.3×	165	4.9k
Roberto Iacovelli	2.1k 0.9×	1.2k 1.0×	2.6k 2.5×	712 1.0×	1.5k 2.2×	224	4.6k
Hendrik Bläker	1.8k 0.7×	870 0.7×	634 0.6×	840 1.2×	878 1.2×	136	3.6k
Ki Byung Song	3.0k 1.3×	593 0.5×	1.5k 1.4×	1.7k 2.4×	818 1.2×	183	4.2k

Countries citing papers authored by Davendra Sohal

Since Specialization

Citations

This map shows the geographic impact of Davendra Sohal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Davendra Sohal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Davendra Sohal more than expected).

Fields of papers citing papers by Davendra Sohal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Davendra Sohal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Davendra Sohal. The network helps show where Davendra Sohal may publish in the future.

Co-authorship network of co-authors of Davendra Sohal

This figure shows the co-authorship network connecting the top 25 collaborators of Davendra Sohal. A scholar is included among the top collaborators of Davendra Sohal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Davendra Sohal. Davendra Sohal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Patel, Sameer H., Davendra Sohal, Katherine A. Guthrie, et al.. (2025). Chemotherapy dose density is prognostic for overall survival in patients with resectable pancreas cancer: A landmark analysis of SWOG 1505. Cancer. 131(4). e35759–e35759. 2 indexed citations

Wattenberg, Max M., Ignacio Garrido‐Laguna, Jesse Lee, et al.. (2024). Intratumoral Cell Neighborhoods Coordinate Outcomes in Pancreatic Ductal Adenocarcinoma. Gastroenterology. 166(6). 1114–1129. 11 indexed citations

Fakih, Marwan, Davendra Sohal, Justin Call, et al.. (2024). 625P Initial results from the phase I, first-in-human study of the covalent, PI3Kα inhibitor TOS-358 in patients with solid tumors, expressing PI3Kα mutations or amplifications. Annals of Oncology. 35. S499–S500. 2 indexed citations

Kim, Kevin, Anwaar Saeed, Davendra Sohal, et al.. (2024). An open-label, multicenter study investigating RP2 oncolytic immunotherapy in combination with second-line systemic atezolizumab combined with bevacizumab in patients with locally advanced unresectable or metastatic hepatocellular carcinoma.. Journal of Clinical Oncology. 42(16_suppl). TPS4191–TPS4191. 2 indexed citations

Christenson, Eric S., Daruka Mahadevan, Syed Mohammad Ali Kazmi, et al.. (2024). A phase 1b study of NC410 in combination with pembrolizumab in immune checkpoint inhibitor (ICI) naïve, and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer.. Journal of Clinical Oncology. 42(16_suppl). 2538–2538. 2 indexed citations

Abdou, Yara, Paula R. Pohlmann, Richard T. Maziarz, et al.. (2024). A phase 1, first-in-human study of autologous monocytes engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2-overexpressing solid tumors.. Journal of Clinical Oncology. 42(16_suppl). TPS2682–TPS2682. 4 indexed citations

Perez, Bradford A., Raid Aljumaily, Thomas U. Marron, et al.. (2024). Phase I study of peposertib and avelumab with or without palliative radiotherapy in patients with advanced solid tumors. ESMO Open. 9(2). 102217–102217. 10 indexed citations

Kovacic, Melinda Butsch, et al.. (2024). Disparities in Clinical Trial Participation: A Cross-Sectional Survey of Cancer Patients at a Midwest Academic Medical Center. Current Oncology. 31(9). 5367–5373. 1 indexed citations

Kharofa, Jordan, David Haslam, Allison Weiss, et al.. (2023). Analysis of the fecal metagenome in long‐term survivors of pancreas cancer. Cancer. 129(13). 1986–1994. 14 indexed citations

10.

Olson, Daniel J., Ecaterina E. Dumbrava, Syma Iqbal, et al.. (2023). 738 A phase 1/2 study investigating the safety and efficacy of autologous TAC T cells in subjects with unresectable, locally advanced or metastatic claudin 18.2+ solid tumors. SHILAP Revista de lepidopterología. A831–A831. 1 indexed citations

11.

Vikas, Praveen, Hans Messersmith, Carolyn C. Compton, et al.. (2023). Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of College of American Pathologists Guideline. Journal of Clinical Oncology. 41(10). 1943–1948. 57 indexed citations

12.

Sohal, Davendra, Jordan Kharofa, Sameer H. Patel, et al.. (2023). An adaptive approach to neoadjuvant therapy to maximize resection rates for pancreatic adenocarcinoma: A phase II trial.. Journal of Clinical Oncology. 41(4_suppl). TPS771–TPS771. 1 indexed citations

13.

Bhambhvani, Hriday P., Julia S. Johansen, Shalini Makawita, et al.. (2023). Development of an artificial intelligence-derived histologic signature associated with adjuvant gemcitabine treatment outcomes in pancreatic cancer. Cell Reports Medicine. 4(4). 101013–101013. 9 indexed citations

14.

Turner, Kevin M., Aaron M. Delman, Jordan Kharofa, et al.. (2022). Radiation therapy in borderline resectable pancreatic cancer: A review. Surgery. 172(1). 284–290. 4 indexed citations

15.

Eng, Cathy, Emerson Y. Chen, Jane E. Rogers, et al.. (2021). Moving Beyond the Momentum: Innovative Approaches to Clinical Trial Implementation. JCO Oncology Practice. 17(10). 607–614. 6 indexed citations

16.

Mahdi, Haider, Navid Hafez, Deborah B. Doroshow, et al.. (2021). Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations). JCO Precision Oncology. 5(5). 1432–1442. 56 indexed citations

17.

Pishvaian, Michael J., R Joseph Bender, Lola Rahib, et al.. (2018). Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative. Clinical Cancer Research. 24(20). 5018–5027. 149 indexed citations

18.

Sohal, Davendra, Shiva Shrotriya, Mohamed E. Abazeed, Michael Cruise, & Alok A. Khorana. (2016). Molecular characteristics of biliary tract cancer. Critical Reviews in Oncology/Hematology. 107. 111–118. 29 indexed citations

19.

Nischal, Sangeeta, Sanchari Bhattacharyya, Maximilian Christopeit, et al.. (2012). Methylome Profiling Reveals Distinct Alterations in Phenotypic and Mutational Subgroups of Myeloproliferative Neoplasms. Cancer Research. 73(3). 1076–1085. 42 indexed citations

20.

Isufi, Iris, Mahesh Seetharam, Li Zhou, et al.. (2007). Transforming Growth Factor- β Signaling in Normal and Malignant Hematopoiesis. Journal of Interferon & Cytokine Research. 27(7). 543–552. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact